The Clinical Question of a ZOMETA® Multiple Myeloma Patient Who Is Responding Well To Treatment

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Multiple Myeloma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Multiple Myeloma Patient Case Study - Marie

Marie T.

Aged 62 years
Lives and works on a family farm
Enjoys walking her dogs with her husband

How would you continue to address Marie's bone health?

After 8 months of VAD, Marie's disease is responding well to treatment
Now that Marie is ready to discontinue VAD therapy, she is questioning whether she needs to continue receiving ZOMETA

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.